Nkarta Therapeutics Inc. has recently presented data for their allogeneic CAR natural killer (NK) cell therapy, NKX-019, targeting CD19 for treating autoimmune disease through B-cell targeting.
Transition Bio Inc. and Voyager Therapeutics Inc. have entered into a drug discovery collaboration and license option agreement for novel, selective small molecules for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) with TDP-43 pathology.
Researchers at Carl von Ossietzky Universität Oldenburg generated retinal pigment epithelial cell lines lacking three RPGR isoforms and examined whether they showed the defects in ciliary structure and actin turnover known to occur in retinitis pigmentosa.
Researchers at Triana Biomedicines Inc. presented the preclinical characterization of TRI-611, a CNS-penetrant molecular glue degrader targeting ALK in models of ALK fusion-positive non-small-cell lung cancer.
Commit Biologics ApS has released promising results from a nonhuman primate (NHP) study demonstrating proof of concept for its proprietary bispecific complement engager (BiCE) platform.
City Therapeutics Inc. has submitted a clinical trial application (CTA) to the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a phase I study of CITY-FXI, an investigational RNAi therapeutic targeting factor XI (FXI) for the treatment of thromboembolic diseases.
Researchers from Monte Rosa Therapeutics Inc. reported preclinical efficacy data on MRT-8102, a selective NEK7 molecular glue degrader, designed to treat inflammatory diseases.
Inje University has described 3-phosphoinositide-dependent protein kinase 1 (PDPK1) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Keythera (Suzhou) Pharmaceuticals Co. Ltd. has divulged mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of urticaria, allergy, asthma, pruritus, arthritis, nasal polyps, dermatitis and irritable bowel syndrome, among others.
Eluciderm Inc. has identified compounds acting as inhibitors of Wnt signaling and/or poly(ADP-ribose) polymerase tankyrase-2 (TNKS2; PARP5B) and/or poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) and/or PARP-2 (ARTD2) reported to be useful for the treatment of cancer, acne, rosacea, psoriasis and scleroderma.
RSS
